论文部分内容阅读
目的探讨米非司酮在治疗盆腔子宫内膜异位症腹腔镜手术后患者的临床疗效。方法将78例子宫内膜异位症腹腔镜手术后患者,随机分为两组:孕三烯酮组38例,服用孕三烯酮2.5mg,2次/周,连续6个月;米非司酮组40例,服用米非司酮10mg/d,两组均于手术后第1次月经来潮第1天开始用药,1次/d,疗程6个月;所有患者随访1~3年。比较应用其治疗子宫内膜异位症的疗效、不良反应情况及对肝功能的影响。结果两组患者痛经症状均得到不同程度缓解,孕三烯酮组和米非司酮组完全缓解率分别为85.0%和87.5%,差异无统计学意义(P>0.05);孕三烯酮组和米非司酮组累积复发率分别为7.5%和5.0%,差异无统计学意义(P>0.05)。服用米非司酮患者仅有3例转氨酶升高,孕三烯酮组有10例转氨酶升高。结论米非司酮用于盆腔子宫内膜异位症手术后巩固治疗,安全、有效,且不良反应小。
Objective To investigate the clinical efficacy of mifepristone in the treatment of patients with pelvic endometriosis after laparoscopic surgery. Methods 78 patients with endometriosis after laparoscopic surgery were randomly divided into two groups: gestrinone group 38 cases, taking gestrinone 2.5mg, 2 times / week for 6 months; Chlordiazepoxide group of 40 patients, taking mifepristone 10mg / d, two groups were in the first postoperative menstrual cramps on the first day of medication, 1 / d, course of 6 months; all patients were followed up for 1 to 3 years. The application of its treatment of endometriosis efficacy, adverse reactions and the impact on liver function. Results The dysmenorrhea symptoms of both groups were relieved to some extent. The complete remission rates of gestrinone and mifepristone groups were 85.0% and 87.5%, respectively, with no significant difference (P> 0.05). The gestrinone group And mifepristone group were 7.5% and 5.0%, respectively, with no significant difference (P> 0.05). Only 3 cases of patients with mifepristone transaminase increased, gestrinone group, 10 cases of elevated transaminases. Conclusion Mifepristone is safe and effective in the treatment of pelvic endometriosis after operation, and its adverse reaction is small.